EKEhud Karavani

Ehud Karavani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ehud Karavani has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Michal Rosen-Zvi

    AI for Accelerated Healthcare and Life Sciences Discovery IBM Research‐Israel Haifa Israel

    3 shared publications
  • Andrew A. Pieper

    Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, USA

    2 shared publications
  • Feixiong Cheng

    Cleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA

    2 shared publications
  • James B. Leverenz

    Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, USA

    2 shared publications
  • Jeffrey Cummings

    Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada, Las Vegas, Las Vegas, USA

    2 shared publications
  • Jielin Xu

    Cleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA

    2 shared publications

Latest Publications

  • Open Access

    Alzheimer’s disease target and drug discovery by leveraging multiomics and electronic health data

    by Yuan Hou, Yichen Li, Pengyue Zhang, Noah Lorincz-Comi, Dhruv Gohel, Fan Fan, Yunguang Qiu, Jun Yang, Xin Chen, Wenqiang Song, et al.

    Despite prolific genomic data from individuals with Alzheimer’s disease (AD), translation into treatments has lagged. Here we applied Mendelian randomization to multiple AD genome-wide association studies and functional multiomics datasets to nominate druggable targets, identifying 19 targets for individuals of European ancestry and 7 for African ancestry. This included epoxide hydrolase 2 (EPHX2), for which we identified a protective missense variant (p.Arg287Gln). Experiments in induced pluripotent stem cell-derived neurons and cerebral organoids from patients with AD validated the protective role of p.Arg287Gln via reduced levels of EPHX2 and phosphorylated tau (pTau-181). Pharmacological inhibition of EPHX2 improved cognitive performance in the 5xFAD mouse model of AD. Finally, by leveraging electronic health data from 111,680 patients with mild cognitive impairment, we identified 12 drugs associated with reduced AD incidence, including trazodone (targeting ADRA1A) and baclofen (targeting GABBR1). Thus, integrating multiomics data, functional validation and electronic health data identifies new approaches for treating AD.

  • Open Access

    Single‐microglia transcriptomic transition network‐based prediction and real‐world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease

    by Jielin Xu, Wenqiang Song, Zhenxing Xu, Michael M. Danziger, Ehud Karavani, Chengxi Zang, Xin Chen, Yichen Li, Isabela M Rivera Paz, Dhruv Gohel, et al.

    INTRODUCTION: High microglial heterogeneities hinder the development of microglia‐targeted treatment for Alzheimer's disease (AD). METHODS: We integrated 0.7 million single‐nuclei RNA‐sequencing transcriptomes from human brains using a variational autoencoder. We predicted AD‐relevant microglial subtype‐specific transition networks for disease‐associated microglia (DAM), tau microglia, and neuroinflammation‐like microglia (NIM). We prioritized drugs by specifically targeting microglia‐specific transition networks and validated drugs using two independent real‐world patient databases. RESULTS: We identified putative AD molecular drivers (e.g., SYK , CTSB , and INPP5D ) in transition networks of DAM and NIM. Via specifically targeting NIM, we identified that usage of ketorolac was associated with reduced AD incidence in both MarketScan (hazard ratio [HR] = 0.89) and INSIGHT (HR = 0.83) Clinical Research Network databases, mechanistically supported by ketorolac‐treated transcriptomic data from AD patient induced pluripotent stem cell–derived microglia. DISCUSSION: This study offers insights into the pathobiology of AD‐relevant microglial subtypes and identifies ketorolac as a potential anti‐inflammatory treatment for AD. Highlights: An integrative analysis of ≈ 0.7 million single‐nuclei RNA‐sequencing transcriptomes from human brains identified Alzheimer's disease (AD)–relevant microglia subtypes. Network‐based analysis identified putative molecular drivers (e.g., SYK, CTSB, INPP5D ) of transition networks between disease‐associated microglia (DAM) and neuroinflammation‐like microglia (NIM). Via network‐based prediction and population‐based validation, we identified that usage of ketorolac (a US Food and Drug Administration–approved anti‐inflammatory medicine) was associated with reduced AD incidence in two independent patient databases. Mechanistic observation showed that ketorolac treatment downregulated the Type‐I interferon signaling in patient induced pluripotent stem cell–derived microglia, mechanistically supporting its protective effects in real‐world patient databases.


  • Open Access

    Improving Inverse Probability Weighting by Post-calibrating Its Propensity Scores

    by Rom Gutman, Ehud Karavani, Yishai Shimoni

    Theoretical guarantees for causal inference using propensity scores are partially based on the scores behaving like conditional probabilities. However, prediction scores between zero and one do not necessarily behave like probabilities, especially when output by flexible statistical estimators. We perform a simulation study to assess the error in estimating the average treatment effect before and after applying a simple and well-established postprocessing method to calibrate the propensity scores. We observe that postcalibration reduces the error in effect estimation and that larger improvements in calibration result in larger improvements in effect estimation. Specifically, we find that expressive tree-based estimators, which are often less calibrated than logistic regression-based models initially, tend to show larger improvements relative to logistic regression-based models. Given the improvement in effect estimation and that postcalibration is computationally cheap, we recommend its adoption when modeling propensity scores with expressive models.


  • Open Access

    Causalvis: Visualizations for Causal Inference

    by Grace Guo, Ehud Karavani, Alex Endert, Bum Chul Kwon

    Causal inference is a statistical paradigm for quantifying causal effects using observational data. It is a complex process, requiring multiple steps, iterations, and collaborations with domain experts. Analysts often rely on visualizations to evaluate the accuracy of each step. However, existing visualization toolkits are not designed to support the entire causal inference process within computational environments familiar to analysts. In this paper, we address this gap with Causalvis, a Python visualization package for causal inference. Working closely with causal inference experts, we adopted an iterative design process to develop four interactive visualization modules to support causal inference analysis tasks. The modules are then presented back to the experts for feedback and evaluation. We found that Causalvis effectively supported the iterative causal inference process. We discuss the implications of our findings for designing visualizations for causal inference, particularly for tasks of communication and collaboration.


  • Open Access

    Trends in clinical characteristics and associations of severe non-respiratory events related to SARS-CoV-2

    by Tal El-Hay, Ehud Karavani, Asaf Peretz, Matan Ninio, Sivan Ravid, Michal Chorev, Michal Rosen-Zvi, Tal Patalon, Yishai Shimoni, Anil Jain

    Background The 2019 novel coronavirus (SARS-CoV-2) is reported to result in both respiratory and non-respiratory severe health outcomes, but quantitative assessment of the risk – while adjusting for underlying risk driven by comorbidities – is not yet established. Methods A retrospective observational study using electronic health records of 9,344,021 individuals across the U.S. with at-least 1 year of clinical history and followed up throughout 2020. Results 131,329 individuals were associated with SARS-CoV-2 infection by January 6, 2021 in three distinct surges. While the age and number of preexisting conditions had decreased throughout the pandemic, the characteristics of those who experienced severe health events did not. During the second surge, between June 7 and November 18, 2020, 425,988 individuals in the base cohort were admitted to emergency rooms or hospitals. Among them, 15,486 were detected with SAR-CoV-2 within few days of admission. Significant adjusted odds ratios were observed between SARS-CoV-2 infection and the following severe health events: respiratory (4.38, 95% confidence interval 4.16– 4.62), bacterial pneumonia (3.25, 2.76–3.83), sepsis (1.71, 1.53–1.91), renal (1.69, 1.57–1.83), hematologic/immune (1.32, 1.20–1.45), neurological (1.23, 1.09–1.38). Conclusions SARS-CoV-2 infection among hospitalized patients is associated with non-negligible increased risk of severe events including multiple non-respiratory ones. These associations, which complement recent studies, are persistent even after accounting for sources of selection and confounding bias, increasing the confidence they are not spurious.

  • Predicting Breast Cancer by Applying Deep Learning to Linked Health Records and Mammograms

    by Ayelet Akselrod-Ballin, Michal Chorev, Yoel Shoshan, Adam Spiro, Alon Hazan, Roie Melamed, Ella Barkan, Esma Herzel, Shaked Naor, Ehud Karavani, et al.

    A deep learning algorithm trained on a linked data set of mammograms and electronic health records achieved breast cancer detection accuracy comparable to radiologists as defined by the Breast Canc... BackgroundComputational models on the basis of deep neural networks are increasingly used to analyze health care data. However, the efficacy of traditional computational models in radiology is a ma...